[1]陈莉,安海燕,张承承,等.基于网络药理学探讨苍术-黄柏药对治疗糖尿病肾病的作用机制[J].西部中医药,2023,36(12):77-82.[doi:10.12174/j.issn.2096-9600.2023.12.17]
　CHEN Li,AN Haiyan,ZHANG Chengcheng,et al.Network Pharmacology-based Discussion on Cangzhu-Huangbo in the Treatment of Diabetic Kidney Disease[J].Western Journal of Traditional Chinese Medicine,2023,36(12):77-82.[doi:10.12174/j.issn.2096-9600.2023.12.17]
点击复制

基于网络药理学探讨苍术-黄柏药对治疗糖尿病肾病的作用机制
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
36
期数:
2023年12期
页码:
77-82
栏目:
出版日期:
2023-12-15

文章信息/Info

Title:
Network Pharmacology-based Discussion on Cangzhu-Huangbo in the Treatment of Diabetic Kidney Disease
作者:
陈莉, 安海燕, 张承承, 郭晓媛
北京中医药大学东方医院，北京 100078
Author(s):
CHEN Li, AN Haiyan, ZHANG Chengcheng, GUO Xiaoyuan
Dongfang Hospital of Beijing University of Chinese Medicine, Beijing 100078, China
关键词:
糖尿病肾病; 网络药理学; 苍术; 黄柏; 作用机制
Keywords:
diabetic kidney disease; network pharmacology; the mechanism
分类号:
R587.2
DOI:
10.12174/j.issn.2096-9600.2023.12.17
文献标志码:
A
摘要:
目的基于网络药理学探讨苍术-黄柏药对治疗糖尿病肾病（diabetic kidney disease，DKD）的有效成分、潜在作用靶点及作用机制。 方法通过中药系统药理学平台检索苍术-黄柏药对的有效成分、潜在作用靶点，在人类基因数据库和人类孟德尔遗传数据库数据库筛选与糖尿病肾病有关的疾病靶点，然后绘制Venn图，得出苍术-黄柏药对治疗DKD的共同靶点，借助Cytoscape 3.7.2构建“药对成分-靶点-疾病”可视化网络。利用STRING平台绘制交集靶点PPI网络，并利用MCODE插件筛选核心子网络，在David数据库针对核心靶点进行GO及KEGG通路富集分析。 结果检索筛选出苍术-黄柏药对有效活性成分28个，潜在作用靶点202个，其中，苍术-黄柏药对治疗DKD的133个，通过PPI核心子网络发现包括JUN、MMP9、CXCL8、TNF、VEGFA、PTGS2、AKT1、IL-6等在内的52个靶点可能是药对治疗DKD的核心靶点，KEGG通路富集分析发现苍术-黄柏药对治疗DKD的作用机制可能与磷脂酰肌醇3激酶-蛋白激酶B（phosphatidylinositol 3 kinase-protein kinase B，PI3K-Akt）、肿瘤坏死因子（tumor necrosis factor，TNF）、Toll样受体（toll-like receptor，TLR）及缺氧诱导因子1（hypoxia inducible factor-1，HIF-1）等88条信号通路有关。 结论苍术-黄柏药对治疗DKD体现了多成分、多靶点、多途径的特点，为进一步探讨其作用机制提供了参考。
Abstract:
ObjectiveTo study the effective components, potential targets and mechanism of Cangzhu(Atractylodis rhizoma)-Huangbo(Phellodendri Chinensis cortex) in the treatment of diabetic kidney disease (DKD) based on network pharmacology. MethodsThe active ingredients and potential targets of Cangzhu-Huangbo were searched from TCMSP, the targets related to DKD were screened in the Genecards and OMIM databases, and the common targets of the drug pair for DKD were obtained by drawing Venn diagrams. The drug pair components-target-disease visualization network was constructed via Cytoscape 3.7.2. STRING platform was utilized to construct PPI network of the intersection targets, MCODE was applied to screen the core subnetwork, GO and KEGG pathway enrichment analysis of the core targets were conducted in David database. ResultsAll 28 active ingredients and 202 potential targets were identified from the drug pair Cangzhu-Huangbo, among them, there were 133 targets belonging to the drug pair in the treatment of DKD, 52 targets including JUN, MMP9, CXCL8, TNF, VEGFA, PTGS2, AKT1, IL-6 found by PPI core subnetwork might be the core ones of the drug pair in the treatment of DKD, KEGG pathway enrichment analysis indicated that the mechanism of the drug pair in treating DKD might be related to 88 signaling pathways including PI3K-Akt, TNF, TLR and HIF-1. ConclusionThe couplet medicine Cangzhu-Huangbo in the treatment of DKD reflect the characteristics of many ingredients, mangy targets and many pathways, and it could provide the reference for further discussion of its mechanism.

相似文献/References:

[1]林晓芬,黄燕璇.益肾汤联合厄贝沙坦及胰激肽原酶治疗早期糖尿病肾病的疗效观察[J].西部中医药,2013,26(07):68.
　LIN Xiaofen,HUANG Yanxuan.Clinical Observation on YiShenTang Combined with Irbesartan and Pancreatic Kininogenase in the Treatment for Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):68.
[2]王学琦,李丰华,张荣华,等.温肾汤治疗早期糖尿病肾病80例[J].西部中医药,2013,26(09):62.
　WANG Xueqi,LI Fenghua,ZHANG Ronghua,et al.WenShenTang for 80 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):62.
[3]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病有效性及安全性的系统评价[J].西部中医药,2014,27(01):77.
　REN Fang,XU Houqian.Systematic Review of the Effectiveness and Safety of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2014,27(12):77.
[4]丁夏楠,许筠△,苏建平,等.益肾逐瘀方治疗糖尿病肾病蛋白尿37例[J].西部中医药,2014,27(04):96.
　DING Xianan,XU Jun,SU Jianping,et al.Treatment for Proteinuria of 37 Patients with Diabetic Nephropathy by Kidney-invigorating Stagnation-dispelling Prescription[J].Western Journal of Traditional Chinese Medicine,2014,27(12):96.
[5]肖远莉.循证护理的优效性及影响因素分析———来自终末期糖尿病肾病患者血液透析的证据[J].西部中医药,2014,27(08):127.
[6]刘涛.缬沙坦联合复方丹参滴丸对早期2型糖尿病肾病患者尿微量白蛋白的影响[J].西部中医药,2015,28(05):106.
[7]连琯,史晓伟.当归补血汤合金水宝治疗早期糖尿病肾病16例临床观察[J].西部中医药,2013,26(06):68.
　LIAN Guan,SHI Xiaowei.Clinical Observation on DangGui BuXueTang and JinShuiBao in Treating 16 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):68.
[8]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病随机对照试验报告质量评价[J].西部中医药,2013,26(12):1.
　REN Fang,XU Houqian.Quality Evaluation of the Report for Randomized Controlled Trials of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):1.
[9]朱苗蕊,指导：金智生.糖脂平治疗早期糖尿病肾病60例疗效观察*[J].西部中医药,2013,26(03):74.
　ZHU Miaorui,Director: JIN Zhisheng.Clinical Observation on TangZhiPing in Treating 60 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):74.
[10]马天寿.血塞通联合西药治疗糖尿病肾病80例[J].西部中医药,2013,26(08):96.
　MA Tianshou.XueSaiTong Injection and Western Medicine in Treating 80 Cases of Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):96.

备注/Memo

备注/Memo:
作；陈莉 （1995—），女，硕士学位。研究方向：肾病的中西医结合治疗。国家自然科学基金（81904144）。
更新日期/Last Update: 2023-12-15